StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) shareholders

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
74M of 66M shares
Institutional holders
256
101 new, 27 sold out
Net institutional buying
21M
In Q2 2026
Insider trades, 12 months
0 buys · 145 sales
Net sold $343.71M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Harwin Peter Evan
Joint filing with Fairmount Funds Management LLC (19.47%), Kiselak Tomas (19.47%) and 1 more
14,572,91719.50%13D (active) amendmentJul 1, 2026
Fairmount Funds Management LLC
Joint filing with Kiselak Tomas (19.99%), Harwin Peter Evan (19.99%) and 1 more
13,665,08019.99%13D (active) amendmentApr 30, 2026
Tomas Kiselak
Joint filing with Fairmount Funds Management LLC (19.99%), Peter Evan Harwin (19.99%) and 2 more
11,162,74119.99%13D (active) amendmentSep 17, 2025
Abigail P. Johnson
Joint filing with FMR LLC (15.35%)
5,512,30015.35%13G (passive)Oct 7, 2024
Bong Y. Koh
Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more
4,909,6199.90%13G (passive) amendmentSep 30, 2025
Venrock Healthcare Capital Partners III, L.P.
Joint filing with VHCP Co-Investment Holdings III, LLC (7.40%), Venrock Healthcare Capital Partners EG, L.P. (7.40%) and 4 more
4,556,9527.40%13G (passive) amendmentJun 30, 2026
Bong Y Koh
Joint filing with Venrock Healthcare Capital Partners III, L.P. (11.10%), VHCP Co-Investment Holdings III, LLC (11.10%) and 4 more
4,148,42811.10%13G (passive) amendmentFeb 10, 2025
Capital World Investors3,401,6395.60%13G (passive)Jun 30, 2026
BlackRock, Inc.3,175,4836.60%13G (passive)Dec 31, 2025
Roderick Wong
Joint filing with RTW Investments, LP (5.20%)
3,139,0305.20%13G (passive)Jun 30, 2026
Viking Global Investors LP
Joint filing with Viking Global Opportunities Parent GP LLC (5.30%), Halvorsen Ole Andreas (5.30%) and 1 more
2,666,6905.30%13G (passive) amendmentMar 31, 2026
Shabet Rose Sharon
Joint filing with Viking Global Investors LP (5.50%), Viking Global Opportunities Parent GP LLC (5.50%) and 2 more
2,666,6905.50%13G (passive)Sep 17, 2025
Roderick Wong, M.D.
Joint filing with RTW Investments, LP (5.20%)
1,945,6495.20%13G (passive)Mar 31, 2025
Deep Track Biotechnology Master Fund, Ltd.
Joint filing with Deep Track Capital, LP (5.07%), David Kroin (5.07%)
1,896,7805.07%13G (passive)May 6, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ORKAValueChange% of portfolio
FMR LLC9,057,64513.68%$862.02M+1,626,2420.04%
BlackRock, Inc.4,990,1817.54%$474.92M+1,463,0940.01%
VR Adviser, LLC4,148,4286.27%$394.81M–11.97%
Fairmount Funds Management LLC3,705,2625.60%$352.63M–23.31%
Capital World Investors3,401,6395.14%$323.73MNew0.04%
Rtw Investments, LP3,139,0304.74%$298.74M+1,080,8822.55%
State Street Corp2,673,0904.04%$254.38M+1,059,6290.01%
Vanguard Capital Management LLC2,360,9713.57%$224.69M+501,3400.00%
Paradigm Biocapital Advisors LP2,144,5263.24%$204.09M−175,7903.82%
Deep Track Capital, LP1,926,0002.91%$183.30M−108,2032.67%
Bellevue Group AG1,657,1902.50%$157.71M+1,150,1823.32%
Franklin Resources Inc1,621,4512.45%$154.31M+617,3950.03%
Remedium Capital Partners, LLC1,565,6612.36%$149.00M–32.99%
Ra Capital Management, L.P.1,554,5972.35%$147.95MNew1.29%
Viking Global Investors LP1,503,4782.27%$143.09M−1,163,2120.41%
Geode Capital Management, LLC1,429,9542.16%$136.11M+475,0870.01%
Jupiter Topco LLC1,375,8442.08%$130.97MNew0.05%
Perceptive Advisors LLC1,345,0632.03%$128.01M−50,4381.92%
Polar Capital Holdings Plc1,228,6091.86%$116.93M+180,9160.28%
Citadel Advisors LLC1,119,0111.69%$106.50M+111,4740.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202625674M100.0%101 / 9447 / 2727M6M
Q1 202618453M79.9%63 / 6531 / 209M6M
Q4 202514353M79.8%46 / 5317 / 810M3M
Q3 202510546M68.8%32 / 3221 / 813M2M
Q2 20258134M52.0%25 / 2714 / 155M2M
Q1 20257132M48.0%16 / 2812 / 105M4M
Q4 20246631M46.9%29 / 208 / 59M2M
Q3 20244225M37.1%42 / 00 / 025M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

259 funds held ORKA in Q2 2026, 32% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ORKAValue% of fundAs of
Vanguard Total Stock Market Index Fund1,724,6922.60%$164.14M0.01%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,555,0022.35%$147.99M1.38%Jun 30, 2026
SMALLCAP World Fund Inc1,527,5922.31%$145.38M0.15%Jun 30, 2026
iShares Russell 2000 ETF1,300,2021.96%$123.74M0.15%Jun 30, 2026
Fidelity Growth Company Fund1,221,0461.84%$71.47M0.07%May 31, 2026
Select Health Care Portfolio833,1001.26%$48.76M0.84%May 31, 2026
Fidelity Advisor Biotechnology Fund737,3861.11%$71.17M3.24%Jul 31, 2026
Fidelity Small Cap Growth Fund685,7181.04%$66.18M0.75%Jul 31, 2026
Vanguard Extended Market Index Fund580,9530.88%$55.29M0.06%Jun 30, 2026
Select Biotechnology Portfolio562,6830.85%$32.93M0.63%May 31, 2026
Fidelity Small Cap Index Fund550,7430.83%$53.15M0.16%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.451,1180.68%$42.93M0.36%Jun 30, 2026
iShares Russell 2000 Growth ETF449,1950.68%$42.75M0.28%Jun 30, 2026
Fidelity Advisor Health Care Fund428,0000.65%$41.31M1.32%Jul 31, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.381,1280.58%$36.27M0.39%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Lawrence Otto KleinChief Executive Officer, Director923,1281.39%Nov 2, 2026
Joana GoncalvesChief Medical Officer31,7710.05%Nov 16, 2026
Arjun AgarwalSenior Vice President, Finance14,2190.02%Nov 13, 2026
Paul T. QuinlanGeneral Counsel29,9950.05%Oct 20, 2026
Laura Lee SandlerChief Operating Officer235,4780.36%Sep 15, 2026
Larry Todd EdwardsChief Commercial Officer100,0000.15%Aug 25, 2026
Kristine M. BallDirector0–Nov 13, 2026
Funds Management LLC FairmountDirector, 10% owner––Jul 1, 2026
Healthcare Fund II L.P. FairmountDirector, 10% owner––Jul 1, 2026
Tomas KiselakDirector, 10% owner7,258,67210.96%Jul 1, 2026
Healthcare Co-Invest III L.P. FairmountDirector, 10% owner––Jul 1, 2026
Peter Evan HarwinDirector, 10% owner2,936,9224.44%Jul 1, 2026
Carl DambkowskiDirector38,7430.06%Jun 12, 2026
Christopher Nathan MartinDirector––Jun 3, 2026
Samarth KulkarniDirector––Jun 3, 2026
Cameron TurtleDirector85,2330.13%Jun 3, 2025
VHCP Management III, LLC10% owner4,025,5466.08%Feb 27, 2025
VHCP Co-Investment Holdings III, LLC10% owner––Feb 27, 2025
Venrock Healthcare Capital Partners III, L.P.10% owner––Feb 27, 2025
VHCP Management EG, LLC10% owner––Feb 27, 2025
Venrock Healthcare Capital Partners EG, L.P.10% owner––Feb 27, 2025
Nimish P. Shah10% owner––Feb 27, 2025
Bong Y. Koh10% owner0–Feb 27, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−500$105.86$52.93K31,771
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−200$103.36$20.67K32,271
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−300$102.47$30.74K32,471
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−1,900$101.53$192.90K32,771
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−1,500$100.48$150.72K34,671
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−2,600$99.52$258.74K36,171
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Option exercise+3,500$7.80$27.30K38,771
Joana Goncalves
Chief Medical Officer
Nov 16, 2026Option exercise+3,500$6.84$23.94K35,271
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Sale(10b5-1 plan)−100$107.00$10.70K14,219
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Sale(10b5-1 plan)−958$106.18$101.72K14,319
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Sale(10b5-1 plan)−6,842$105.28$720.33K15,277
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Sale(10b5-1 plan)−799$104.25$83.30K22,119
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Sale(10b5-1 plan)−801$103.16$82.63K22,918
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Sale(10b5-1 plan)−500$101.98$50.99K23,719
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Option exercise+1,458$34.39$50.14K24,219
Arjun Agarwal
Senior Vice President, Finance
Nov 12, 2026Option exercise+8,542$12.50$106.78K22,761
Kristine M. Ball
Director
Nov 12, 2026Sale(10b5-1 plan)−200$106.98$21.40K0
Kristine M. Ball
Director
Nov 12, 2026Sale(10b5-1 plan)−2,500$106.05$265.13K200
Kristine M. Ball
Director
Nov 12, 2026Sale(10b5-1 plan)−10,765$105.31$1.13M2,700
Kristine M. Ball
Director
Nov 12, 2026Sale(10b5-1 plan)−2,039$104.16$212.39K13,465
Kristine M. Ball
Director
Nov 12, 2026Sale(10b5-1 plan)−1,300$103.09$134.02K15,504
Kristine M. Ball
Director
Nov 12, 2026Sale(10b5-1 plan)−1,196$102.10$122.11K16,804
Kristine M. Ball
Director
Nov 12, 2026Option exercise+18,000$6.84$123.12K18,000
Lawrence Otto Klein
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−300$98.40$29.52K923,128
Lawrence Otto Klein
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−756$97.45$73.68K923,428
Lawrence Otto Klein
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−2,442$96.70$236.15K924,184
Lawrence Otto Klein
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−15,036$95.64$1.44M926,626
Lawrence Otto Klein
Chief Executive Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−6,466$94.77$612.79K941,662
Lawrence Otto Klein
Chief Executive Officer, Director
Nov 2, 2026Option exercise+25,000$7.80$195.00K948,128
Paul T. Quinlan
General Counsel
Oct 20, 2026Sale(10b5-1 plan)−3,000$79.49$238.47K29,995
Paul T. Quinlan
General Counsel
Oct 20, 2026Sale(10b5-1 plan)−4,100$78.79$323.04K32,995
Paul T. Quinlan
General Counsel
Oct 20, 2026Sale(10b5-1 plan)−1,000$77.20$77.21K37,095
Paul T. Quinlan
General Counsel
Oct 20, 2026Sale(10b5-1 plan)−500$76.12$38.06K38,095
Paul T. Quinlan
General Counsel
Oct 20, 2026Sale(10b5-1 plan)−400$74.90$29.96K38,595
Paul T. Quinlan
General Counsel
Oct 20, 2026Option exercise+9,000$7.80$70.20K38,995
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Sale(10b5-1 plan)−200$77.71$15.54K31,771
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Sale(10b5-1 plan)−700$76.67$53.67K31,971
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Sale(10b5-1 plan)−1,400$75.48$105.68K32,671
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Sale(10b5-1 plan)−1,847$74.69$137.96K34,071
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Sale(10b5-1 plan)−2,853$73.89$210.81K35,918
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Option exercise+3,500$7.80$27.30K38,771
Joana Goncalves
Chief Medical Officer
Oct 15, 2026Option exercise+3,500$6.84$23.94K35,271
Arjun Agarwal
Senior Vice President, Finance
Oct 12, 2026Sale(10b5-1 plan)−200$82.83$16.57K14,219
Arjun Agarwal
Senior Vice President, Finance
Oct 12, 2026Sale(10b5-1 plan)−1,958$81.86$160.27K14,419
Arjun Agarwal
Senior Vice President, Finance
Oct 12, 2026Sale(10b5-1 plan)−2,100$80.76$169.60K16,377
Arjun Agarwal
Senior Vice President, Finance
Oct 12, 2026Sale(10b5-1 plan)−5,741$80.03$459.45K18,477
Arjun Agarwal
Senior Vice President, Finance
Oct 12, 2026Option exercise+1,458$34.39$50.14K24,218
Arjun Agarwal
Senior Vice President, Finance
Oct 12, 2026Option exercise+8,541$12.50$106.76K22,760
Lawrence Otto Klein
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−200$84.78$16.96K923,128
Lawrence Otto Klein
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−8,554$84.03$718.75K923,328
Lawrence Otto Klein
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−16,246$83.40$1.35M931,882
Lawrence Otto Klein
Chief Executive Officer, Director
Oct 1, 2026Option exercise+25,000$7.80$195.00K948,128
Paul T. Quinlan
General Counsel
Sep 21, 2026Sale(10b5-1 plan)−3,832$93.32$357.60K33,263
Paul T. Quinlan
General Counsel
Sep 21, 2026Sale(10b5-1 plan)−601$94.44$56.76K32,662
Paul T. Quinlan
General Counsel
Sep 21, 2026Sale(10b5-1 plan)−2,667$95.31$254.19K29,995
Paul T. Quinlan
General Counsel
Sep 21, 2026Sale(10b5-1 plan)−2,900$92.37$267.87K37,095
Paul T. Quinlan
General Counsel
Sep 21, 2026Option exercise+10,000$7.80$78.00K39,995
Arjun Agarwal
Senior Vice President, Finance
Sep 21, 2026Sale(10b5-1 plan)−533$95.75$51.03K14,219
Laura Lee Sandler
Chief Operating Officer
Sep 15, 2026Sale−906$95.71$86.71K235,478
Paul T. Quinlan
General Counsel
Sep 15, 2026Sale−1,039$95.71$99.44K29,995

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.67%
6M shares short
Days to cover
7.1
At 1M shares a day
Change since last report
+5.8%
From 6M shares
Short volume, 20 days
51.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oruka Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 138,421 shares on Sep 25, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Lawrence Otto Klein
Director, Officer
Nov 2, 202625,000$2.42MNov 2, 2026Exercise of Stock Options
Joana Goncalves
Officer
Oct 15, 202621,000$1.61MOct 15, 2026Exercise of Stock Options
Arjun Agarwal
Officer
Oct 13, 20269,999$821.02KOct 12, 2026Exercise of Stock Options
Lawrence Otto Klein
Director, Officer
Oct 1, 202625,000$2.08MOct 1, 2026Exercise of Stock Options
Arjun Agarwal
Officer
Sep 21, 2026533$50.61KSep 21, 2026Restricted Stock Units
Lawrence Otto Klein
Director, Officer
Sep 1, 202675,000$6.95MSep 1, 2026Exercise of Stock Options
Laura Lee Sandler
Officer
Sep 1, 20265,000$463.10KSep 1, 2026Exercise of Stock Options
Paul T. Quinlan
Officer
Aug 14, 202671,000$7.68MAug 14, 2026Exercise of Stock Options
Joana Goncalves
Officer
Jul 15, 202621,000$1.84MJul 15, 2026Exercise of Stock Options
Arjun Agarwal
Officer
Jul 13, 202628,588$2.48MJul 13, 2026Exercise of Stock Options
Healthcare Fund II L.P. Fairmount
Director, 10% Stockholder
Jul 1, 20263,553,410$300.01MJul 1, 2026Conversion of Series B Non-Voting Convertible Preferred Stock
Carl Dambkowski
Director
Jun 11, 202635,000$2.24MJun 11, 2026Partnership Distribution
Carl Dambkowski
Director
May 21, 2026105,000$6.37MMay 21, 2026Exercise of Stock Options
Arjun Agarwal
Officer
May 18, 202622,206$1.38MMay 18, 2026Exercise of Stock Options
Laura Lee Sandler
Officer
May 1, 202610,000$684.10KMay 1, 2026Exercise of Stock Options

See a number that looks wrong?